{
    "clinical_study": {
        "@rank": "92514", 
        "arm_group": {
            "arm_group_label": "MDS patients", 
            "description": "MDS patients who were treated with decitabine"
        }, 
        "brief_summary": {
            "textblock": "To assess the efficacy of decitabine and identify predictors for response to decitabine\n      therapy."
        }, 
        "brief_title": "Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or\n           secondary) based on the World Health Organization (WHO) classifications\n\n        -  Survival and response Analysis\n\n        -  Response rate\n\n        -  Overall survival\n\n        -  Leukemia free survival"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or\n             secondary) based on the World Health Organization (WHO) classifications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or\n        secondary) based on the World Health Organization (WHO) classifications"
            }
        }, 
        "enrollment": {
            "#text": "1", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045654", 
            "org_study_id": "2014-01-086"
        }, 
        "intervention_browse": {
            "mesh_term": "Decitabine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "email": "smcjunhojang@gmail.com", 
                "last_name": "Jun Ho Jang, M.D.", 
                "phone": "82-2-3410-0918"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Division of Hematology Oncology, Samsung Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients", 
        "overall_contact": {
            "email": "jh21.jang@samsung.com", 
            "last_name": "Jun Ho Jang, Pf"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Jun Ho Jang, Pf", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "International Working Group (IWG) response criteria", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045654"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Jun Ho Jang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "measured from the date of decitabine therapy to the date of death or the last follow-up visit", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "the date of decitabine therapy to the date of death or leukemic transformation", 
                "measure": "Leukemia free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}